Aprea Therapeutics, Inc. (APRE)

NASDAQ: APRE · IEX Real-Time Price · USD
0.493
+0.015 (3.16%)
Dec 9, 2022 1:22 PM EST - Market closed
3.16%
Market Cap 25.30M
Revenue (ttm) n/a
Net Income (ttm) -117.98M
Shares Out 34.66M
EPS (ttm) -1.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 76,894
Open 0.49
Previous Close 0.477
Day's Range 0.474 - 0.52
52-Week Range 0.331 - 4.296
Beta 0.17
Analysts Buy
Price Target 3.06 (+521.3%)
Earnings Date Nov 14, 2022

About APRE

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts. [Read more]

Industry Biotechnology
IPO Date Oct 3, 2019
Employees 17
Stock Exchange NASDAQ
Ticker Symbol APRE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for APRE stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 521.32% from the latest price.

Price Target
$3.06
(521.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeuti...

1 month ago - GlobeNewsWire

Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR)...

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA da...

2 months ago - GlobeNewsWire

Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeuti...

3 months ago - GlobeNewsWire

Aprea Therapeutics (APRE) Stock Soars as Wedbush Sets $3 Price Target

Wedbush analyst Robert Driscoll just gave a huge upside target for APRE stock. Here's why this is significant for the biotech sector.

5 months ago - InvestorPlace

Karolinska Development's portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals

STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based bi...

6 months ago - GlobeNewsWire

Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage res...

6 months ago - GlobeNewsWire

Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operat...

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mu...

8 months ago - GlobeNewsWire

Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst...

10 months ago - Zacks Investment Research

Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Mai...

BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) --  Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant...

11 months ago - GlobeNewsWire

Aprea (APRE) Reports FDA Removal of Clinical Hold on Study

The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.

11 months ago - Zacks Investment Research

FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies

The FDA removed the full clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) trial evaluating the combination of eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid malign...

1 year ago - Benzinga

Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...

1 year ago - GlobeNewsWire

Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematolog...

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant ...

1 year ago - GlobeNewsWire

Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO

Aprea Therapeutics Inc (NASDAQ: APRE) presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors.  The trial is evaluating the safe...

1 year ago - Benzinga

Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Cong...

BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mu...

1 year ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?

Investors need to pay close attention to Aprea Therapeutics (APRE) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...

1 year ago - GlobeNewsWire

Aprea Therapeutics Drops After FDA Clinical Hold On Another Blood Cancer Study

After instituting a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) myeloid malignancies program, the FDA has placed a clinical hold on Aprea's lymphoid malignancy study.  The trial is ...

1 year ago - Benzinga

Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant ...

1 year ago - GlobeNewsWire

Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials

The FDA has instituted a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) clinical trials of eprenetapopt (APR-246) combined with azacitidine in its myeloid malignancy programs.  Approxi...

1 year ago - Benzinga

Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant ...

1 year ago - GlobeNewsWire

Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Tr...

Aprea Therapeutics Inc (NASDAQ: APRE) has announced results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant myelodysp...

1 year ago - Benzinga

Implied Volatility Surging for Aprea (APRE) Stock Options

Investors need to pay close attention to Aprea (APRE) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal

Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.

1 year ago - Zacks Investment Research

Karolinska Development's portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary effica...

STOCKHOLM, SWEDEN – June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase 1/2...

1 year ago - GlobeNewsWire